MDM2 Antagonists Counteract Drug-Induced DNA Damage

Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage in melanoma cells and patient-derived xenografts. Among the tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilgelm, Anna E., Cobb, Priscilla, Malikayil, Kiran, Flaherty, David, Andrew Johnson, C., Raman, Dayanidhi, Saleh, Nabil, Higgins, Brian, Vara, Brandon A., Johnston, Jeffrey N., Johnson, Douglas B., Kelley, Mark C., Chen, Sheau-Chiann, Ayers, Gregory D., Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652019/
https://www.ncbi.nlm.nih.gov/pubmed/29030058
http://dx.doi.org/10.1016/j.ebiom.2017.09.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652019/
https://www.ncbi.nlm.nih.gov/pubmed/29030058
http://dx.doi.org/10.1016/j.ebiom.2017.09.016

Ejemplares similares